Compare Citius Pharmaceuticals Inc (CTXR) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Expedia Group Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Expedia Group Inc trades at $274.22 (market cap $32.42B). The key difference: Expedia Group Inc is far larger — about 2380.3× Citius Pharmaceuticals Inc's market cap, and Expedia Group Inc pays a 0.71% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Expedia Group Inc for 47 Days on average.
| CTXR | EXPE | |
|---|---|---|
Market Cap | $13.62M | $32.42B |
Volume | 132,438 | 1,940,671 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $339.13 |
52-Week Low | $0.48 | $188.51 |
Typical Hold Time | 17 Days | 47 Days |
Enterprise Value | $3.79M | $30.98B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Expedia Group (EXPE) trades at $270.13, up 4.35% with strong technical momentum above key support levels. The company demonstrates robust fundamentals with consistent earnings beats, 90.43% gross margins, and improving cash flow trends. Recent news highlights competitive threats from AI travel agents but also strategic partnerships and positive growth outlook. Analyst consensus remains mixed with a $335.06 price target representing 24% upside potential from current levels.
Expedia presents a compelling value opportunity with reasonable valuation multiples (P/E 16.99, P/S 2.18) and strong profitability metrics. However, investors face significant competitive risks from AI disruption and recent layoffs indicate operational challenges. The stock's upside depends on maintaining booking growth momentum against increasing industry competition and technological disruption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
